Non-erythrocyte agglutination anti-PD-L1/CD47 bispecific antibody and application thereof in anti-tumour treatment

A PD-L1, bispecific antibody technology, applied in the medical field, can solve problems such as disease deterioration

Active Publication Date: 2021-09-10
INST OF MICROBIOLOGY - CHINESE ACAD OF SCI
View PDF8 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] In addition, almost all tumor cells have the ability to increase the expression of their own CD47 protein, which not only inhibits the normal immune killing function of various im

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Non-erythrocyte agglutination anti-PD-L1/CD47 bispecific antibody and application thereof in anti-tumour treatment
  • Non-erythrocyte agglutination anti-PD-L1/CD47 bispecific antibody and application thereof in anti-tumour treatment
  • Non-erythrocyte agglutination anti-PD-L1/CD47 bispecific antibody and application thereof in anti-tumour treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0039] PD-1 molecule is an important member of CD28 family, which also includes CD28, CTLA-4, ICOS and so on. PD-1 molecules are expressed in activated B cells, T cells, and bone marrow cells, etc., and are a type I transmembrane protein with a molecular weight of about 55kDa. Currently, PD-1 has two ligands, namely PD-L1 and PD-L2. PD-1 inhibits T cell activity by interacting with (PD-L1 and / or PD-L2). PD-L1 can be highly expressed on the surface of a variety of tumor cells. Through the interaction between PD-1 and PD-L1, it can inhibit the functional activity of tumor infiltrating lymphocytes, including TCR-mediated T cell proliferation and cytokine secretion levels Therefore, it is used by a variety of tumors as an important mechanism for tumor cells to escape the surveillance of the immune system. The use of antibodies to specifically block the interaction between PD-1 and (PD-L1 and / or PD-L2) can activate T cells in a suppressed state, release the function of T cells, an...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a non-erythrocyte agglutination anti-PD-L1/CD47 bispecific antibody and application thereof in anti-tumour treatment. Specifically, the invention provides an anti-PD-L1/CD47 bispecific antibody or an antigen binding fragment thereof; the anti-PD-L1/CD47 bispecific antibody can be specifically bound with PD-L1 and CD47 molecules; binding of PD-L1 and PD-1 and binding of CD47 and SIRP alpha can be blocked at the same time after binding; T cells and macrophages are further activated to achieve the biological effects of resisting tumours and the like; and meanwhile, the antibody does not cause erythrocyte agglutination.

Description

technical field [0001] The invention belongs to the field of medicine, in particular to an antibody or an antigen-binding fragment thereof, which specifically recognizes programmed cell death 1 ligand 1 (programmed cell death 1 ligand 1, PD-L1) and human Cluster of Differentiation 47 (Cluster of Differentiation, CD47) can be used as an immune activator to stimulate the immune response of the body, thereby producing anti-tumor and other diseases, and at the same time, the antibody does not cause erythrocyte agglutination. Background technique [0002] In 2011, cancer surpassed heart disease as the leading cause of death worldwide. The WHO announced in December 2013 that the number of new cancer patients worldwide has exceeded 14 million each year, which is a substantial increase compared with the 2008 statistics of 12.7 million. During the same period, the number of deaths of cancer patients also increased, from 7.6 million in the past to 8.2 million. In 2013, the immune an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K16/46A61K39/395A61P35/00
CPCC07K16/2827C07K16/2803A61P35/00C07K2317/31C07K2317/565C07K2317/56C07K2317/76C07K2317/92A61K2039/505
Inventor 严景华史瑞谭曙光高福马素芳
Owner INST OF MICROBIOLOGY - CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap